source
- Gilead places CAR-T program on partial hold after ICANS cases; Agios delays PDUFA submissionGilead announced a partial clinical hold on its CAR-T therapy after several patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). The hold will pause enrollment and…
- AstraZeneca hints restructuring may trim R&D budget and move trials to emerging marketsAstraZeneca's chief executive Pascal Soriot told journalists that the company's new restructuring program could lead to cost reductions in research and development and may see some clinical trials…